Oncotarget

Research Papers:

GSTM1, GSTT1, and GSTP1 polymorphisms and colorectal cancer risk in Polish nonsmokers

Justyna Klusek _, Anna Nasierowska-Guttmejer, Artur Kowalik, Iwona Wawrzycka, Piotr Lewitowicz, Magdalena Chrapek and Stanisław Głuszek

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:21224-21230. https://doi.org/10.18632/oncotarget.25031

Metrics: PDF 391 views  |   HTML 701 views  |   ?  


Abstract

Justyna Klusek1, Anna Nasierowska-Guttmejer2, Artur Kowalik3, Iwona Wawrzycka1,4, Piotr Lewitowicz2, Magdalena Chrapek5 and Stanisław Głuszek1,4

1Department of Surgery and Surgical Nursery with a Research Laboratory, Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland

2Department of Pathology, Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland

3Department of Molecular Diagnostics, Holy Cross Cancer Centre, Kielce, Poland

4Department of General, Oncological and Endocrinological Surgery, Voivodeship Hospital, Kielce, Poland

5Department of Probability Calculus and Statistics, Institute of Mathematics, Jan Kochanowski University, Kielce, Poland

Correspondence to:

Justyna Klusek, email: justynaklusek@tlen.pl

Keywords: colorectal cancer; GSTT1; GSTM1; GSTP1; gene polymorphism

Received: September 15, 2017     Accepted: March 19, 2018     Published: April 20, 2018

ABSTRACT

Glutathione S-transferase (GST) enzymes are responsible for cellular detoxification of many carcinogens and are important anticancer elements. This study assessed potential relationships between GSTM1, GSTT1, and GSTP1 polymorphisms and colorectal cancer (CRC) risk in Polish nonsmokers. We also analyzed the influence of GST gene polymorphisms on CRC clinical and histopathological features. Our study included 197 CRC patients and 104 healthy controls. GSTM1, GSTT1, and GSTP1 polymorphisms were evaluated using qPCR. Polymorphism frequencies observed in our control group corresponded to those in other European populations. The GSTM1 null and GSTT1 null genotypes were observed with similar frequencies in both CRC patients and controls (GSTM1 null: 46.7% vs. 45.2%; GSTT1 null: 15.7% vs. 20.2%). GSTP1 Ile/Ile, Ile/Val, and Val/Val genotype frequencies were respectively 42.1%, 48.2%, and 9.6% in patients and 48.1%, 42.3%, and 9.6% in controls. GSTT1 polymorphism correlated with higher tumor grade in CRC patients, and the GSTM1 null/null genotype was associated with more frequent metastasis to lymph nodes (pN classification). Our results suggest that GST gene polymorphisms may influence CRC tumor grade and stage.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25031